Cosmetic cross-reference

50-99-7

CAS 50-99-7

50-99-7 (CAS 50-99-7) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
4
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
50-99-7
CAS Number
50-99-7
UNII
5SL0G7R0OK
InChIKey
GZCGUPFRVQAUEE-SLPGGIOYSA-N
ChEMBL ID
CHEMBL448805
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
GLUCOSEAnhydrous Dextrose
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE PharmGKB 5 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

COMT (PA117) rs4680
Genotypes AA + AG is associated with increased concentrations of glucose in children as compared to genotype GG.
Evidence: -; PMID 25048416
CRTC2 (PA142672073) rs8450
Genotypes AA + AG are associated with increased concentrations of glucose in people with Transplantation as compared to genotype GG.
Evidence: -; PMID 26644205
SLCO1B1 (PA134865839) rs4149056
Genotype TT is associated with concentrations of glucose in healthy individuals.
Evidence: -; PMID 29748863
CRTC2 (PA142672073) rs12117078
Genotype GG is not associated with concentrations of glucose in people with Transplantation as compared to genotypes CC + CG.
Evidence: -; PMID 26644205
RABEP1 (PA134884097) rs1000940
Genotypes AG + GG is associated with decreased concentrations of glucose in people with Bipolar Disorder, Depressive Disorder, Psychotic Disorders and schizoaffective disorder as compared to genotype AA.
Evidence: -; PMID 28694205
SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
GLUCOSE 4850 SU MTHSPL
Anhydrous Dextrose 349730 SU MTHSPL
ANHYDROUS DEXTROSE 349730 SU MTHSPL
anhydrous dextrose 349730 SU MTHSPL
glucose 4850 IN RXNORM
SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abscess glucose LLT C0000833
Abscess glucose PT C0000833
Acidosis glucose LLT C0001122
Acidosis glucose PT C0001122
Administration site infection glucose LLT C1735864
Administration site infection glucose PT C1735864
Agitation glucose LLT C0085631
Agitation glucose PT C0085631
Anaphylactic shock glucose LLT C0002792
Anaphylactic shock glucose PT C0002792
Asthenia glucose LLT C0004093
Asthenia glucose PT C0004093
Body temperature increased glucose LLT C0015967
Body temperature increased glucose PT C0015967
Body temperature increased glucose LLT C0015967
Body temperature increased glucose PT C0015967
Body temperature increased glucose LLT C0015967
Body temperature increased glucose PT C0015967
Cardiac failure congestive glucose LLT C0018802
Cardiac failure congestive glucose PT C0018802
Central nervous system disorder glucose LLT C0007682
Chills glucose LLT C0085593
Chills glucose PT C0085593
Coma glucose LLT C0009421
Coma glucose PT C0009421
Confusional state glucose LLT C0009676
Confusional state glucose PT C0009676
Confusional state glucose LLT C0009676
Confusional state glucose PT C0009676
Convulsion glucose LLT C0036572
Convulsion glucose PT C0036572
Dehydration glucose LLT C0011175
Dehydration glucose PT C0011175
Dehydration glucose LLT C0011175
Dehydration glucose PT C0011175
Diabetic hyperosmolar coma glucose LLT C0020457
Diabetic hyperosmolar coma glucose PT C0020457
Diuresis glucose LLT C0012797
Dizziness glucose LLT C0012833
Dizziness glucose PT C0012833
Extravasation glucose LLT C0015376
Extravasation glucose PT C0015376
Extravasation glucose LLT C0015376
Extravasation glucose PT C0015376
Extravasation glucose LLT C0015376
Extravasation glucose PT C0015376
Feeling abnormal glucose PT C1443060
Feeling abnormal glucose PT C1443060
Fluid overload glucose LLT C0546817
Fluid overload glucose PT C0546817
Fluid overload glucose LLT C0546817
Fluid overload glucose PT C0546817
Fluid overload glucose LLT C0546817
Fluid overload glucose PT C0546817
Fluid retention glucose PT C0268000
Flushing glucose LLT C0016382
Flushing glucose PT C0016382
Glycosuria glucose LLT C0017979
Glycosuria glucose PT C0017979
Haemolysis glucose LLT C0019054
Haemolysis glucose PT C0019054
Headache glucose LLT C0018681
Headache glucose PT C0018681
Hyperglycaemia glucose LLT C0020456
Hyperglycaemia glucose PT C0020456
Hypernatraemia glucose LLT C0020488
Hypernatraemia glucose PT C0020488
Hypersensitivity glucose LLT C0020517
Hypersensitivity glucose PT C0020517
Hypertension glucose LLT C0020538
Hypertension glucose PT C0020538
Hypoglycaemia glucose LLT C0020615
Hypoglycaemia glucose PT C0020615
Hypokalaemia glucose LLT C0020621
Hypokalaemia glucose PT C0020621
Hypovolaemia glucose LLT C0546884
Hypovolaemia glucose PT C0546884
Infection glucose LLT C0009450
Infection glucose PT C0009450
Injection site infection glucose LLT C0221714
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 50-99-7 used for in pharmaceutical contexts?

50-99-7 (CAS 50-99-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 50-99-7?

50-99-7 has SIDER side-effect terms including Abscess, Acidosis, Administration site infection, Agitation, Anaphylactic shock; no DrugCentral/FAERS adverse-event association rows are rendered for this page. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 50-99-7 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Glucose with EU status "permitted".

What clinical phase is 50-99-7 in?

No phase 1-4 clinical development badge is rendered for 50-99-7 because the matched compound identifier rows do not contain a max-phase value.